Proceedings of the National Academy of Sciences, Volume 123, Issue 13, March 2026. SignificanceThe last 25 y have seen a remarkable number of new anticancer therapies specifically targeting tyrosine kinases, which frequently drive tumorigenesis when hyperactive. While these therapies have brought undeniable improvements in survival time ...
PNAS published a clinical update in Research Highlights on 25 Mar 2026.
The item focuses on Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies.
Review the original article for the full source wording and details.